Compare RGTIW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGTIW | SNY |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | France |
| Employees | 140 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 119.4B |
| IPO Year | N/A | N/A |
| Metric | RGTIW | SNY |
|---|---|---|
| Price | $15.73 | $47.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $61.50 |
| AVG Volume (30 Days) | 850.8K | ★ 2.8M |
| Earning Date | 03-11-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 3.32% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | N/A | ★ 8.67 |
| Revenue | $11,892,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $6.47 |
| P/E Ratio | ★ N/A | $5.56 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.28 | $44.62 |
| 52 Week High | $4.75 | $60.12 |
| Indicator | RGTIW | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 50.39 | 41.35 |
| Support Level | $11.00 | $47.70 |
| Resistance Level | $13.80 | $48.45 |
| Average True Range (ATR) | 2.17 | 0.65 |
| MACD | 0.24 | -0.07 |
| Stochastic Oscillator | 59.82 | 31.80 |
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. The company offers full-stack quantum computing platform as a cloud service to a wide range of end-users, directly through its Rigetti QCS platform, and also through cloud service providers. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, the company derives the majority of its revenue from the United States.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.